Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Nuijen

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
International Journal of Pharmaceutics|February 29, 2000
In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BSB Nuijen, M Bouma, R E Henrar, et al.
Drug Development and Industrial Pharmacy|October 20, 2004
Development and manufacture of diacetylmorphine/caffeine sachets for inhalation via 'chasing the dragon' by heroin addictsM G Klous, B Nuijen, W van den Brink, et al.
Investigational New Drugs|September 20, 2001
Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devicesB Nuijen, M Bouma, C Manada, et al.
Anti-Cancer Drugs|January 6, 2001
Pharmaceutical development of anticancer agents derived from marine sourcesB Nuijen, M Bouma, C Manada, et al.
Die Pharmazie|December 17, 2008
Purity profile of the indoloquinone anticancer agent EO-9 and chemical stability of EO-9 freeze dried with 2-hydroxypropyl-beta-cyclodextrinS C van der Schoot, L D Vainchtein, B Nuijen, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 24, 2017
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasmaM Herbrink, B Thijssen, M J X Hillebrand, et al.
Die Pharmazie|February 4, 2006
Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devicesM W J Den Brok, B Nuijen, J L García, et al.
Drug Development and Industrial Pharmacy|July 30, 2008
Complexation study of the anticancer agent EO-9 with 2-hydroxypropyl-beta-cyclodextrinJ H Beijnen, S C van der Schoot, B Nuijen, et al.
International Journal of Pharmaceutics|October 3, 2006
EO-9 bladder instillations: formulation selection based on stability characteristics and in vitro simulation studiesS C van der Schoot, L D Vainchtein, J H Beijnen, et al.
Drug Development and Industrial Pharmacy|November 9, 2001
Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide FB Nuijen, M Bouma, H Talsma, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
International Journal of Pharmaceutics|February 29, 2000
In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BSB Nuijen, M Bouma, R E Henrar, et al.
Drug Development and Industrial Pharmacy|October 20, 2004
Development and manufacture of diacetylmorphine/caffeine sachets for inhalation via 'chasing the dragon' by heroin addictsM G Klous, B Nuijen, W van den Brink, et al.
Investigational New Drugs|September 20, 2001
Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devicesB Nuijen, M Bouma, C Manada, et al.
Anti-Cancer Drugs|January 6, 2001
Pharmaceutical development of anticancer agents derived from marine sourcesB Nuijen, M Bouma, C Manada, et al.
Die Pharmazie|December 17, 2008
Purity profile of the indoloquinone anticancer agent EO-9 and chemical stability of EO-9 freeze dried with 2-hydroxypropyl-beta-cyclodextrinS C van der Schoot, L D Vainchtein, B Nuijen, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 24, 2017
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasmaM Herbrink, B Thijssen, M J X Hillebrand, et al.
Die Pharmazie|February 4, 2006
Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devicesM W J Den Brok, B Nuijen, J L García, et al.
Drug Development and Industrial Pharmacy|July 30, 2008
Complexation study of the anticancer agent EO-9 with 2-hydroxypropyl-beta-cyclodextrinJ H Beijnen, S C van der Schoot, B Nuijen, et al.
International Journal of Pharmaceutics|October 3, 2006
EO-9 bladder instillations: formulation selection based on stability characteristics and in vitro simulation studiesS C van der Schoot, L D Vainchtein, J H Beijnen, et al.
Drug Development and Industrial Pharmacy|November 9, 2001
Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide FB Nuijen, M Bouma, H Talsma, et al.
Pageof 4